HOOKIPA Pharma Inc. (HOOK): Price and Financial Metrics
GET POWR RATINGS... FREE!
HOOK Stock Price Chart Interactive Chart >
HOOK Price/Volume Stats
|Current price||$6.76||52-week high||$20.00|
|Prev. close||$6.55||52-week low||$6.01|
|Day high||$6.82||Avg. volume||290,915|
|50-day MA||$7.15||Dividend yield||N/A|
|200-day MA||$11.11||Market Cap||176.25M|
HOOKIPA Pharma Inc. (HOOK) Company Bio
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
Most Popular Stories View All
HOOK Latest News Stream
|Loading, please wait...|
HOOK Latest Social Stream
View Full HOOK Social Stream
Latest HOOK News From Around the Web
Below are the latest news stories about HOOKIPA Pharma Inc that investors may wish to consider to help them evaluate HOOK as an investment opportunity.
Photo by tolgart/iStock via Getty Images Having lost more than a fifth of its value yesterday, HOOKIPA Pharma ([[HOOK]] -16.8%) is continuing the slide in reaction to the company’s updated data from the Phase 1/2 study for HB-200 in the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers. The company evaluated...
HOOKIPA Pharma ([[HOOK]] -7.1%) has sharply today after announcing an abstract that includes data for its lead assets HB-201 and HB-202 in advanced Human Papillomavirus 16-positive (HPV16+) cancers.The abstract will be part of an oral presentation scheduled for June 07 at the upcoming 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting.The...
HOOK Price Returns